349 related articles for article (PubMed ID: 12884908)
1. c-Met: structure, functions and potential for therapeutic inhibition.
Ma PC; Maulik G; Christensen J; Salgia R
Cancer Metastasis Rev; 2003 Dec; 22(4):309-25. PubMed ID: 12884908
[TBL] [Abstract][Full Text] [Related]
2. Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition.
Maulik G; Shrikhande A; Kijima T; Ma PC; Morrison PT; Salgia R
Cytokine Growth Factor Rev; 2002 Feb; 13(1):41-59. PubMed ID: 11750879
[TBL] [Abstract][Full Text] [Related]
3. Role of c-MET in upper aerodigestive malignancies--from biology to novel therapies.
Dietrich S; Uppalapati R; Seiwert TY; Ma PC
J Environ Pathol Toxicol Oncol; 2005; 24(3):149-62. PubMed ID: 16050800
[TBL] [Abstract][Full Text] [Related]
4. c-Met and hepatocyte growth factor: potential as novel targets in cancer therapy.
Sattler M; Salgia R
Curr Oncol Rep; 2007 Mar; 9(2):102-8. PubMed ID: 17288874
[TBL] [Abstract][Full Text] [Related]
5. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions.
Ma PC; Kijima T; Maulik G; Fox EA; Sattler M; Griffin JD; Johnson BE; Salgia R
Cancer Res; 2003 Oct; 63(19):6272-81. PubMed ID: 14559814
[TBL] [Abstract][Full Text] [Related]
6. Modulation of the c-Met/hepatocyte growth factor pathway in small cell lung cancer.
Maulik G; Kijima T; Ma PC; Ghosh SK; Lin J; Shapiro GI; Schaefer E; Tibaldi E; Johnson BE; Salgia R
Clin Cancer Res; 2002 Feb; 8(2):620-7. PubMed ID: 11839685
[TBL] [Abstract][Full Text] [Related]
7. [A simple view on lung cancer biology: the MET pathway].
Ruppert AM; Beau-Faller M; Belmont L; Lavolé A; Gounant V; Cadranel J; Wislez M
Rev Mal Respir; 2011 Dec; 28(10):1241-9. PubMed ID: 22152933
[TBL] [Abstract][Full Text] [Related]
8. Downstream signalling and specific inhibition of c-MET/HGF pathway in small cell lung cancer: implications for tumour invasion.
Ma PC; Tretiakova MS; Nallasura V; Jagadeeswaran R; Husain AN; Salgia R
Br J Cancer; 2007 Aug; 97(3):368-77. PubMed ID: 17667909
[TBL] [Abstract][Full Text] [Related]
9. c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention.
Christensen JG; Burrows J; Salgia R
Cancer Lett; 2005 Jul; 225(1):1-26. PubMed ID: 15922853
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
11. Structure, biosynthesis and biochemical properties of the HGF receptor in normal and malignant cells.
Comoglio PM
EXS; 1993; 65():131-65. PubMed ID: 8380735
[TBL] [Abstract][Full Text] [Related]
12. Impaired ligand-dependent MET activation caused by an extracellular SEMA domain missense mutation in lung cancer.
Miao W; Sakai K; Sato H; Imamura R; Jangphattananont N; Takagi J; Nishita M; Minami Y; Matsumoto K
Cancer Sci; 2019 Oct; 110(10):3340-3349. PubMed ID: 31342590
[TBL] [Abstract][Full Text] [Related]
13. Ligand-independent activation of c-Met by fibronectin and α(5)β(1)-integrin regulates ovarian cancer invasion and metastasis.
Mitra AK; Sawada K; Tiwari P; Mui K; Gwin K; Lengyel E
Oncogene; 2011 Mar; 30(13):1566-76. PubMed ID: 21119598
[TBL] [Abstract][Full Text] [Related]
14. The roles of hepatocyte growth factor/scatter factor and met receptor in human cancers (Review).
To CT; Tsao MS
Oncol Rep; 1998; 5(5):1013-24. PubMed ID: 9683803
[TBL] [Abstract][Full Text] [Related]
15. MET: a critical player in tumorigenesis and therapeutic target.
Graveel CR; Tolbert D; Vande Woude GF
Cold Spring Harb Perspect Biol; 2013 Jul; 5(7):. PubMed ID: 23818496
[TBL] [Abstract][Full Text] [Related]
16. Hepatocyte growth factor and Met in tumor biology and therapeutic approach with NK4.
Matsumoto K; Nakamura T; Sakai K; Nakamura T
Proteomics; 2008 Aug; 8(16):3360-70. PubMed ID: 18646008
[TBL] [Abstract][Full Text] [Related]
17. The hepatocyte growth factor/c-Met signaling pathway as a therapeutic target to inhibit angiogenesis.
You WK; McDonald DM
BMB Rep; 2008 Dec; 41(12):833-9. PubMed ID: 19123972
[TBL] [Abstract][Full Text] [Related]
18. The Met receptor tyrosine kinase transduces motility, proliferation, and morphogenic signals of scatter factor/hepatocyte growth factor in epithelial cells.
Weidner KM; Sachs M; Birchmeier W
J Cell Biol; 1993 Apr; 121(1):145-54. PubMed ID: 8384622
[TBL] [Abstract][Full Text] [Related]
19. Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression.
Abounader R; Ranganathan S; Lal B; Fielding K; Book A; Dietz H; Burger P; Laterra J
J Natl Cancer Inst; 1999 Sep; 91(18):1548-56. PubMed ID: 10491431
[TBL] [Abstract][Full Text] [Related]
20. The scatter factor signaling pathways as therapeutic associated target in cancer treatment.
Accornero P; Pavone LM; Baratta M
Curr Med Chem; 2010; 17(25):2699-712. PubMed ID: 20586722
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
